medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2007, Number 6

<< Back Next >>

Acta Pediatr Mex 2007; 28 (6)

Support of cytochrome P450 (CYP2D6) in the use of antipsychotic drug

Flores-Pérez J, Cruz-Reyes IA, Flores-Pérez C

Language: Spanish
References: 28
Page: 278-284
PDF size: 150.24 Kb.


ABSTRACT

Metabolic polymorphism can alter the efficiency of a treatment or influence the occurrence of adverse reactions. Cytochrome 450, includes CYP2D6 which metabolizes 20% of drugs such as antipsychotic and antidepressive.
Several studies have shown significant racial differences in the prevalence of phenotypes of CYP2D6, but there is not enough information on this subject in pediatric populations.
Polymorphism of cytochrome is of great importance in pediatric pharmacotherapy, because of its therapeutic limitations are due to the lack of knowledge of metabolic characterization as well as, the lack of monitoring of the treatment results.
Pharmacogenetic techniques are important inasmuch as they help physicians to prescribe more adequate doses of antipsychotic drugs which are currently effective only in 30% of the patients.
“Personalized medicine” is important in psychiatry in order to optimize the dose of psychoactive drugs, by means of the use of CYP2D6 phenotyping, which allows to classify patients as slow, fast, intermediate and ultrarapid metabolizers.
Phenotyping is done with the use of dextromethorphan as an indicator of the metabolism of CYP2D6. After oral administration of a single 0.5 mg/kg dose of DM, its urinary concentration and that of its metabolite (dextrorphan) are measured with HPLC method for fluorescence detection.


REFERENCES

  1. Miranda E, Ostrosky Wegman P. Bases científicas de las respuestas idiosincrásicas en la terapéutica. El papel del gen CYP2D6. Acta Med Grupo Ángeles 2004;2(1):59-63.

  2. Goshman L, Fish J, Roller K. Clinically significant cytochrome P450 drug interactions. J Pharm Soc Wisconsin 1999;5:23-35.

  3. Leeder S. Pharmacogenetics and pharmacogenomics. Pediatr Clin North Am June 2001;48(3):765-81.

  4. Cytochrome P450 enzyme genotyping: optimizing patient care through pharmacogenetics. Mayo reference services publication. 2005; 30 (9). www.mayoreferenceservices.org/ communique.

  5. Schmid B, Bircher J, Preisig R, Küpfer A. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative Odemethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985;38:618-24.

  6. Gaedigk A, Ryder D, Bradford L, Leeder JS. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the 1584G promoter polymorphism. Clin Chem 2003;49(6):1008-11.

  7. Cytochrome P4502D6 and 2C19, Managing medication dosing and reducing adverse drug reactions. Laboratory Corporation of America. 2006 www.Labcorb.com

  8. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Leeder JS et al. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 1999;9:669-82.

  9. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS, et al. Unique CYP2D6 activity distribution and genotype-phenotype discordance in African Americans. Clin Pharmacol Ther 2002;72:76-89.

  10. Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;18:220-39.

  11. Marinac JS, Foxworth JW, Willsie SK. Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy Black American adult subjects. Ther Drug Monit 1995;17:120-4.

  12. Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP, Lin JS. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in Black Americans. J Clin Invest 1993;91:2150-4.

  13. Warwimolruk S, Patamasucon P, Lee EDJ. Evidence for the polymorphic oxidation of debrisoquine in the Thai population. Br J Clin Pharmacol 1990;29:244-7.

  14. Bertilsson L, Lou Y-Q, Du YL, Liu Y, Kuang T-Y, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol ther 1992;51:388-97.

  15. Linder, M., Russell, A. Prough, Valdes, R. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 1997;43(2):254-66 .

  16. Mendoza R, Wan YJ, Poland RE, Smith M, Zheng Y, Berman N, et al. CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther 2001;70(6):552-60.

  17. Bernard S, Neville K, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP26 in the U.S. population: clinical implications. Oncologist. 2006;11:126-35.

  18. Lares-Asseff I, Sosa- Macias M, Elizondo-Azuela G, Flores- Pérez C, Flores-Pérez J, Bradley-Alvarez F. Phenotypical expression of CYP2D6 In Amerindians of Tepehuano origin from Durango, Mexico. Proc West Pharmacol Soc 2005;48:102-7.

  19. Estévez FE, Giusti MJ, Parrillo S, Prando M. Variabilidad del metabolismo oxidativo de fármacos en la población uruguaya: polimorfismo genético del citocromo P-450 2D6. Rev Méd Urug 1997;13(2):93-100.

  20. Evans W, Relling M, Petros W, Meyer W, Mirro J, Crom WR. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989;45:568-73.

  21. Kennedy MJ, Abdel-Rahman SM, Kashuba AD, Leeder JS. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. J Clin Pharmacol 2004;44(7):708-14.

  22. Anders R. Phenotyping of drug metabolism in infants and children: potentials and problems.. Pediatrics 1999;104(3):640-3. www.pediatrics.org.

  23. De Leon J, Armstrong S, Cozza K. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 AND CYP450 2C19. Psychosomatics 2006;47(1):75-85.

  24. Berecz R., Dorado P, De la Rubia A, Cáceres MC, Degrell I, Llerena A. The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. Current Drug Targets 2004;5:573-9.

  25. Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 2006;58:871-85.

  26. Steijns L, Van Der Weide J. Ultrarapid drug metabolism: PCRbased detection of CYP2D6 gene duplication. Clin Chem 1998;44:914-7.

  27. Findling R, Steiner H, Weller E. Use of antipsychotics in children and adolescents. J Clin Psychiatry 2005;66(suppl 7):29-40.

  28. Flores-Pérez J, Flores-Pérez C, Juárez-Olguín H, Lares-Asseff I, Sosa-Macías M. Determintaion of dextromethorphan and dextrorphan in human urine by high performance liquid chromatography for pharmacogenetic investigations. Chromatographia 2004;59(7/8):481-5.




2020     |     www.medigraphic.com